Company Gaining Traction with Drug Candidate CVSI-007 to Become the Only FDA Approved Treatment for Smokeless Tobacco Addiction LAS VEGAS, NV–(Marketwired – July 20, 2017) – CV Sciences, Inc. (OTCQB: CVSI) (the “Company,” “CV Sciences,” “our” or “we”), highlights a recent clinical study using pharmaceutical grade cannabidiol (CBD) which suggests that CBD […]